However, a study by Miao et al. showed that PBRM1 deficiency is associated with intermediate (n=17) or significant (n=27) response to anti-PD-L1 therapy in a cohort of 63 ccRCC patients, thereby contradicting with our findings [25]. Here, PBRM1 is linked to nonpapillary renal cell carcinoma.